1. Heng BH, Sun Y, Cheah JT, Jong M. The Singapore National Healthcare Group Diabetes Registry--descriptive epidemiology of type 2 diabetes mellitus. Ann Acad Med Singap. 2010;39(5):348-52. [
DOI:10.47102/annals-acadmedsg.V39N5p348] [
PMID]
2. Prasad H, Ryan DA, Celzo MF, Stapleton D. Metabolic syndrome: definition and therapeutic implications. Postgrad Med. 2012;124(1):21-30. [
DOI:10.3810/pgm.2012.01.2514] [
PMID]
3. Teixeira-Lemos E, Nunes S, Teixeira F, Reis F. Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovasc Diabetol. 2011;10(1):12. [
DOI:10.1186/1475-2840-10-12] [
PMID] [
PMCID]
4. Reddy KJ, Singh M, Bangit JR, Batsell RR. The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review. J Cardiovasc Med (Hagerstown). 2010;11(9):633-47. [
DOI:10.2459/JCM.0b013e328333645a] [
PMID]
5. Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, et al. The inflammatory status score including IL-6, TNF-alpha, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol. 2014;51(1):123-31. [
DOI:10.1007/s00592-013-0543-1] [
PMID]
6. Falcao-Pires I, Castro-Chaves P, Miranda-Silva D, Lourenco AP, Leite-Moreira AF. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov Today. 2012;17(15-16):880-9. [
DOI:10.1016/j.drudis.2012.04.007] [
PMID]
7. Blüher M. Adipokines-removing road blocks to obesity and diabetes therapy. Molecular metabolism. 2014;3(3):230-40. [
DOI:10.1016/j.molmet.2014.01.005] [
PMID] [
PMCID]
8. Grunberg JR, Elvin J, Paul A, Hedjazifar S, Hammarstedt A, Smith U. CCN5/WISP2 and metabolic diseases. J Cell Commun Signal. 2018;12(1):309-18. [
DOI:10.1007/s12079-017-0437-z] [
PMID] [
PMCID]
9. Klimontov VV, Bulumbaeva DM, Fazullina ON, Lykov AP, Bgatova NP, Orlov NB, et al. Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. Journal of cell communication signaling. 2020;14(1):101-9. [
DOI:10.1007/s12079-019-00536-4] [
PMID] [
PMCID]
10. Murahovschi V, Pivovarova O, Ilkavets I, Dmitrieva RM, Döcke S, Keyhani-Nejad F, et al. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes. 2015;64(3):856-66. [
DOI:10.2337/db14-0444] [
PMID]
11. Tacke C, Aleksandrova K, Rehfeldt M, Murahovschi V, Markova M, Kemper M, et al. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. Journal of cell communication signaling. 2018;12(3):539-48. [
DOI:10.1007/s12079-017-0427-1] [
PMID] [
PMCID]
12. Barchetta I, Cimini FA, Capoccia D, De Gioannis R, Porzia A, Mainiero F, et al. WISP1 is a marker of systemic and adipose tissue inflammation in dysmetabolic subjects with or without type 2 diabetes. Journal of the Endocrine Society. 2017;1(6):660-70. [
DOI:10.1210/js.2017-00108] [
PMID] [
PMCID]
13. Sahin Ersoy G, Altun Ensari T, Subas S, Giray B, Simsek EE, Cevik O. WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus. The journal of maternal-fetal neonatal medicine. 2017;30(8):942-6. [
DOI:10.1080/14767058.2016.1192118] [
PMID]
14. Horbelt T, Tacke C, Markova M, Herzfeld de Wiza D, Van de Velde F, Bekaert M, et al. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia. 2018;61(9):2054-65. [
DOI:10.1007/s00125-018-4636-9] [
PMID]
15. Jung TW, Kang C, Goh J, Chae SI, Kim HC, Lee TJ, et al. WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol. 2018;233(8):6077-87. [
DOI:10.1002/jcp.26449] [
PMID]
16. Grünberg J. WISP-2-A Novel Adipokine Related to Obesity and Insulin resistance2015.
17. Almario RU, Karakas SE. Roles of circulating WNT-signaling proteins and WNT-inhibitors in human adiposity, insulin resistance, insulin secretion, and inflammation. Horm Metab Res. 2015;47(2):152-7. [
DOI:10.1055/s-0034-1384521] [
PMID]
18. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116(Pt 13):2627-34. [
DOI:10.1242/jcs.00623] [
PMID]
19. Saeidi A, Hackney AC, Tayebi SM, Ahmadian M, Zouhal H. Diabetes, Insulin Resistance, Fetuin-B and Exercise Training. Annals of Applied Sport Science. 2019;7(2):1-2. [
DOI:10.29252/aassjournal.7.2.1] [
PMID] [
PMCID]
20. Saeidi A, Tayebi SM, Khosravi A, Malekian F, Khodamoradi A, Sellami M, et al. Effects of exercise training on type 2-diabetes: the role of Meteorin-like protein. Health Promot Perspect. 2019;9(2):89-91. [
DOI:10.15171/hpp.2019.12] [
PMID] [
PMCID]
21. Saeidi A, Tayebi SM, Khosravi A, Razi O, Sellami M, Abderrahman AB, Zouhal H. Obesity, Fat Mass, Osteopontin and Exercise Training. International Journal of Applied Exercise Physiology. 2019;8(1):177-9.
22. Tayebi SM, Ghanbari-Niaki A, Saeidi A, Hackney AC. Exercise Training, Neuregulin 4 and Obesity. Ann Appl Sport Sci. 2017;5(2):1-2. [
DOI:10.18869/acadpub.aassjournal.5.2.1] [
PMID] [
PMCID]
23. Tayebi SM, Hasannezhad P, Saeidi A, Fadaei MR. Intense Circuit Resistance Training along with Zataria multiflora Supplementation Reduced Plasma Retinol Binding Protein-4 and Tumor Necrosis Factor-α in Postmenopausal Females. Jundishapur J Nat Pharm Prod. 2018;13(2):e38578. [
DOI:10.17795/jjnpp.38578]
24. Tayebi SM, Saeidi A, Fashi M, Pouya S, Khosravi A, Shirvani H, et al. Plasma retinol-binding protein-4 and tumor necrosis factor-α are reduced in postmenopausal women after combination of different intensities of circuit resistance training and Zataria supplementation. Sport Sciences for Health. 2019;15(3):551-8. [
DOI:10.1007/s11332-019-00544-2] [
PMID] [
PMCID]
25. Lujan HL, DiCarlo SE. Physical activity, by enhancing parasympathetic tone and activating the cholinergic anti-inflammatory pathway, is a therapeutic strategy to restrain chronic inflammation and prevent many chronic diseases. Medical hypotheses. 2013;80(5):548-52. [
DOI:10.1016/j.mehy.2013.01.014] [
PMID]
26. Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, Esquivel-Soto J, Morales-Gonzalez A, Esquivel-Chirino C, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci. 2011;12(5):3117-32. [
DOI:10.3390/ijms12053117] [
PMID] [
PMCID]
27. Piya MK, McTernan PG, Kumar S. Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J Endocrinol. 2013;216(1):T1-T15. [
DOI:10.1530/JOE-12-0498] [
PMID]
28. Tayebi SM, Eslami R, Iranshad I, Golmohammadi M. The Effect of Eight Weeks of Circuit Resistance Training on Serum Levels of GPR119 and β-Arrestin1 in Individuals with Type 2 Diabetes. Ann Appl Sport Sci. 2023;11(3):0-.
29. Tayebi SM, Golmohammadi M, Eslami R, Shakiba N, Costa PB. The Effects of Eight Weeks of Circuit Resistance Training on Serum METRNL Levels and Insulin Resistance in Individuals with Type 2 Diabetes. Journal of Diabetes & Metabolic Disorders. 2023. [
DOI:10.1007/s40200-023-01225-1]
30. Pollock ML, Franklin BA, Balady GJ, Chaitman BL, Fleg JL, Fletcher B, et al. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescriptionan advisory from the committee on exercise, rehabilitation, and prevention, council on clinical cardiology, american heart association. Circulation. 2000;101(7):828-33. [
DOI:10.1161/01.CIR.101.7.828] [
PMID]
31. Ogawa K, Sanada K, Machida S, Okutsu M, Suzuki K. Resistance exercise training-induced muscle hypertrophy was associated with reduction of inflammatory markers in elderly women. Mediators of inflammation. 2010;2010. [
DOI:10.1155/2010/171023] [
PMID] [
PMCID]
32. Bahreini A, Fathi R. Comparing the Effect of Eight Weeks of Interval and Continuous Aerobic Training on Serum Levels of WISP1 and TNF-α in Overweight/0bese Girls. Journal of Sport Biomotor Sciences. 2017;10(18):1-12.
33. Chang JS, Kim TH, Kong ID. Exercise intervention lowers aberrant serum WISP-1 levels with insulin resistance in breast cancer survivors: a randomized controlled trial. Sci Rep. 2020;10(1):10898. [
DOI:10.1038/s41598-020-67794-w] [
PMID] [
PMCID]
34. Yaribeygi H, Atkin SL, Sahebkar A. Wingless-type inducible signaling pathway protein-1 (WISP1) adipokine and glucose homeostasis. J Cell Physiol. 2019;234(10):16966-70. [
DOI:10.1002/jcp.28412] [
PMID]
35. Wang S, Zhong Chong Z, Chen Shang Y, Maiese K. WISP1 (CCN4) autoregulates its expression and nuclear trafficking of β-catenin during oxidant stress with limited effects upon neuronal autophagy. Current neurovascular research. 2012;9(2):91-101. [
DOI:10.2174/156720212800410858] [
PMID] [
PMCID]
36. Liu L, Hu J, Yang L, Wang N, Liu Y, Wei X, et al. Association of WISP1/CCN4 with Risk of Overweight and Gestational Diabetes Mellitus in Chinese Pregnant Women. Dis Markers. 2020;2020:4934206. [
DOI:10.1155/2020/4934206] [
PMID] [
PMCID]
37. Mirr M, Owecki M. An Update to the WISP-1/CCN4 Role in Obesity, Insulin Resistance and Diabetes. Medicina (Kaunas). 2021;57(2):100. [
DOI:10.3390/medicina57020100] [
PMID] [
PMCID]
38. Hammarstedt A, Hedjazifar S, Jenndahl L, Gogg S, Grunberg J, Gustafson B, et al. WISP2 regulates preadipocyte commitment and PPARgamma activation by BMP4. Proc Natl Acad Sci U S A. 2013;110(7):2563-8. [
DOI:10.1073/pnas.1211255110] [
PMID] [
PMCID]